Egetis Therapeutics Q1’22: Starting the Year in Style - Redeye

Redeye leaves a comment on the Q1 report from Egetis Therapeutics released earlier this morning. The recent announcement of an upcoming fully guaranteed rights issue capped off an eventful first quarter of the year.

Länk till analysen i sin helhet: https://www.redeye.se/research/839252/egetis-therapeutics-q122-starting-the-year-in-style?utm_source=finwire&utm_medium=RSS